Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Clinical trial NCT04049617 · TERMINATED
Trial details
- NCT number
- NCT04049617
- Sponsor
- Gilead Sciences
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-26
- Primary completion
- 2021-03-30
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.